drugset / Trial / NCT05590221
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Phase 2
Unknown
20 enrolled
Peking University Cancer Hospital & Institute
Shanghai Mingju Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to estimate the efficacy of Relmacabtagene Autoleucel in participants with high-risk large B-cell lymphoma.
Timeline
- Start
- 2023-01-03
- Primary completion
- 2024-02-10
- Completion
- 2024-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relmacabtagene Autoleucel | Cell therapy | 1e+08 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |